In this work, we present a significant step toward in vivo ophthalmic optical coherence tomography and angiography on a photonic integrated chip. The diffraction gratings used in spectral-domain optical coherence tomography can be replaced by photonic integrated circuits comprising an arrayed waveguide grating. Two arrayed waveguide grating designs with 256 channels were tested, which enabled the first chip-based optical coherence tomography and angiography in vivo three-dimensional human retinal measurements. Design 1 supports a bandwidth of 22 nm, with which a sensitivity of up to 91 dB (830 µW) and an axial resolution of 10.7 µm was measured. Design 2 supports a bandwidth of 48 nm, with which a sensitivity of 90 dB (480 µW) and an axial resolution of 6.5 µm was measured. The silicon nitride-based integrated optical waveguides were fabricated with a fully CMOS-compatible process, which allows their monolithic co-integration on top of an optoelectronic silicon chip. As a benchmark for chip-based optical coherence tomography, tomograms generated by a commercially available clinical spectral-domain optical coherence tomography system were compared to those acquired with on-chip gratings. The similarities in the tomograms demonstrate the significant clinical potential for further integration of optical coherence tomography on a chip system.
We present the technological verification of a size-optimized 160-channel, 50-GHz silicon nitride-based AWG-spectrometer. The spectrometer was designed for TM-polarized light with a central wavelength of 850 nm applying our proprietary "AWG-Parameters" tool. For the simulations of AWG layout, the WDM PHASAR photonics tool from Optiwave was used. The simulated results show satisfying optical properties of the designed AWG-spectrometer. However, the high-channel count causes a large AWG size with standard design approaches. To solve this problem we designed a special taper enabling the reduction of AWG structure by about 15% while keeping the same optical properties. The AWG design was fabricated and the measured spectra not only confirm the proposed size-reduction but also the improvement of optical properties of the size-optimized AWG.
As a leading provider of sensing solutions ams AG is developing semiconductor sensors in a wide variety of fields. One of the key competences of ams AG lies in optical sensing. To widen the company’s portfolio in this field we have been developing processes for fully integrated CMOS compatible photonic components based on Si3N4 in the last few years. This contribution will give an overview of the Si3N4 process as a post-processing flow for standard CMOS, some basic photonic building blocks and their properties, and an example for their use in the field of medical applications.
The goal of this paper is to design a low-loss 1 9 32 Y-branch optical splitter for optical transmission systems, using two different design tools employing Beam Propagation Method. As a first step, a conventional 1 9 32 Y-branch splitter was designed and simulated in two-dimensional environment of OptiBPM photonic tool. The simulated optical properties feature high loss, high asymmetric splitting ratio and a large size of the designed structure, too. In the second step of this work we propose an optimization of the conventional splitter design leading to suppression of the asymmetric splitting ratio to onethird of its initial value and to the improvement of the losses by nearly 2 dB. In addition, 50% size reduction of the designed structure was also achieved. This length-optimized low-loss splitter was then modelled in a three-dimensional environment of RSoft photonic tool and the simulated results confirm the strong improvement of the optical properties.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.